GlassScriptPhysician profile
Ronald J Bloom
NPI 1548238835
$18,284.44
in general payments reported to CMS, 2019-2025
65 companies · $2,173 in 2025
The $2,173 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,937 · 2020: $2,149 · 2021: $2,429 · 2022: $3,106 · 2023: $2,125 · 2024: $2,365 · 2025: $2,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,644 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,643.52 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,519.46 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,365.88 | 2019-2025 | Bevespi Aerosphere, Wainua, Farxiga |
| Janssen Pharmaceuticals, INC | $1,273.90 | 2019-2023 | Xarelto |
| Pfizer INC. | $1,233.08 | 2019-2025 | |
| Amgen INC. | $1,185.78 | 2019-2025 | Repatha, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $939.33 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $909.64 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $854.02 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $705.25 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $682.59 | 2022-2025 | |
| Novo Nordisk INC | $666.64 | 2021-2024 | Rybelsus, Ozempic |
| Abbott Laboratories | $609.71 | 2020-2025 | Cardiomems, Freestyle Libre 3, Jot Dx |
| Sanofi-Aventis U.S. LLC | $557.47 | 2019-2023 | |
| Boston Scientific Corporation | $512.03 | 2019-2024 | Watchman Flx, Watchman Access System |
| Esperion Therapeutics, INC. | $506.92 | 2020-2025 | Nexletol |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.